Roche Holding (SWX:ROG) - Cotización, noticias y análisis

Resumen de acción ROG

Roche Holding AG opera en el sector farmacéutico y de diagnóstico en Europa, Norteamérica, Latinoamérica, Asia, África, Australia y Oceanía.

Acerca de la empresa

ROG análisis fundamental
Puntuación del copo de nieve
Valoración	5/6
Crecimiento futuro	3/6
Resultados anteriores	4/6
Salud financiera	4/6
Dividendos	5/6

Recompensas

Cotiza un 63.5% por debajo de nuestra estimación de su valor justo

Se prevé un crecimiento anual de los beneficios de 8.54%

Paga dividendo fiable de 3.87%

Cotiza a buen valor en comparación con empresas similares e industria

Análisis de riesgos

Tiene un alto nivel de endeudamiento

Competidores de Roche Holding AG

Novartis

SWX:NOVN

CHF 202.2b

Dottikon ES Holding

SWX:DESN

CHF 3.5b

Lonza Group

SWX:LONN

CHF 37.3b

AstraZeneca

LSE:AZN

UK£187.6b

Historial de precios y rendimiento

Resumen de todos los máximos históricos, cambios y caídas de precios de Roche Holding
Precios históricos de las acciones
Precio actual de la acción	CHF 258.70
Máximo en 52 semanas	CHF 277.25
Mínimo de 52 semanas	CHF 212.90
Beta	0.13
11 mes Cambio	4.48%
Variación en 3 meses	17.54%
Cambio de 1 año	-3.94%
3Variación en 3 años	-27.03%
Variación en 5 años	-2.03%
Variación desde la OPV	891.19%

Noticias y actualizaciones recientes

Recent updates

We Think Roche Holding (VTX:ROG) Can Stay On Top Of Its Debt

Apr 17

Roche Holding's (VTX:ROG) Shareholders Will Receive A Bigger Dividend Than Last Year

Mar 06

Roche Holding's (VTX:ROG) Shareholders Will Receive A Bigger Dividend Than Last Year

Feb 09

Rentabilidad de los accionistas

	ROG	CH Pharmaceuticals	Mercado CH
7D	5.8%	3.7%	1.3%
1Y	-3.9%	25.6%	7.3%

Rentabilidad vs. Industria: Los resultados de ROG fueron inferiores a los de la industria Swiss Pharmaceuticals, que obtuvo un rendimiento del 19.2% el año pasado.

Rentabilidad vs. Mercado: ROG obtuvo unos resultados inferiores a los del mercado Swiss, que fueron del 4.1% el año pasado.

Volatilidad de los precios

Is ROG's price volatile compared to industry and market?
ROG volatility
ROG Average Weekly Movement	2.6%
Pharmaceuticals Industry Average Movement	3.3%
Market Average Movement	3.3%
10% most volatile stocks in CH Market	5.9%
10% least volatile stocks in CH Market	1.8%

Precio estable de las acciones: ROG no ha tenido una volatilidad de precios significativa en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de ROG (3%) se ha mantenido estable durante el año pasado.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
1896	103,605	Thomas Schinecker	www.roche.com

Roche Holding AG opera en el sector farmacéutico y de diagnóstico en Europa, Norteamérica, Latinoamérica, Asia, África, Australia y Oceanía. La empresa ofrece productos farmacéuticos en las áreas terapéuticas de anemia, tumores sanguíneos y sólidos, dermatología, hemofilia, enfermedades inflamatorias y autoinmunes, trastornos neurológicos, oftalmología, trastornos respiratorios y trasplantes. También está desarrollando productos para diversas áreas terapéuticas.

Resumen de fundamentos de Roche Holding AG

¿Cómo se comparan los beneficios e ingresos de Roche Holding con su capitalización de mercado?
Estadísticas fundamentales de ROG
Capitalización bursátil	CHF 209.07b
Beneficios(TTM)	CHF 11.50b
Ingresos (TTM)	CHF 60.44b

17.9x

Ratio precio-beneficio (PE)

3.4x

Ratio precio-ventas (PS)

¿Está ROG sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de ROG
Ingresos	CHF 60.44b
Coste de los ingresos	CHF 15.60b
Beneficio bruto	CHF 44.84b
Otros gastos	CHF 33.35b
Beneficios	CHF 11.50b

Últimos beneficios comunicados

Dec 31, 2023

Próxima fecha de beneficios

Jul 25, 2024

Beneficios por acción (BPA)	14.42
Margen bruto	74.19%
Margen de beneficio neto	19.02%
Ratio deuda/patrimonio	88.0%

¿Cómo se ha desempeñado ROG a largo plazo?

Ver rendimiento histórico y comparativa

Dividendos

3.7%

Rentabilidad actual por dividendo

67%

Ratio de pagos

Resumen de acción ROG

Recompensas

Análisis de riesgos

Competidores de Roche Holding AG

SWX:NOVN

CHF 202.2b

SWX:DESN

CHF 3.5b

SWX:LONN

CHF 37.3b

LSE:AZN

UK£187.6b

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Roche to Reintroduce Susvimo in the US for People with Neovascular Age-Related Macular Degeneration (nAMD)

Roche Provides Update on Phase II/III SKYSCRAPER-06 Study in Metastatic Non-Small Cell Lung Cancer

Roche Holding AG to Report Q2, 2024 Results on Jul 25, 2024

Roche Announces the European Commission Grants Marketing Authorisation for OCREVUS (Ocrelizumab) Subcutaneous for the Treatment of Relapsing Multiple Sclerosis and Primary Progressive Multiple Sclerosis

Roche Launches New Highly-Sensitive Test to More Easily Diagnostic Patients Who May Have B-Cell Lymphoma

Roche’s Phase III STARGLO study demonstrates Columvi significantly extends survival in people with relapsed or refractory diffuse large B-cell lymphoma

Recent updates

Roche to Reintroduce Susvimo in the US for People with Neovascular Age-Related Macular Degeneration (nAMD)

Roche Provides Update on Phase II/III SKYSCRAPER-06 Study in Metastatic Non-Small Cell Lung Cancer

Roche Holding AG to Report Q2, 2024 Results on Jul 25, 2024

Roche Announces the European Commission Grants Marketing Authorisation for OCREVUS (Ocrelizumab) Subcutaneous for the Treatment of Relapsing Multiple Sclerosis and Primary Progressive Multiple Sclerosis

Roche Launches New Highly-Sensitive Test to More Easily Diagnostic Patients Who May Have B-Cell Lymphoma

Roche’s Phase III STARGLO study demonstrates Columvi significantly extends survival in people with relapsed or refractory diffuse large B-cell lymphoma

Roche Holding AG Announces U.S. Food and Drug Administration Accepted the New Drug Application and Granted Priority Review to Inavolisib, an Investigational, Oral Therapy, in Combination with Palbociclib (Ibrance®) and Fulvestrant

Roche Announces Management and Board Committee Changes

Roche Receives FDA Device Designation for Blood Test Measuring Lp(a)

Roche Reports Positive Phase I Results for Its Dual GLP-1/GIP Receptor Agonist CT-388 in People with Obesity

Roche Announces FDA Approval of One of the First HPV Self- Collection Solutions in the U.S., Expanding Access and Screening Options to Help Eliminate Cervical Cancer

Roche Holding AG Provides Earnings Guidance for the Year 2024

FDA Approves Roche’s Alecensa as the First Adjuvant Treatment for People with ALK-Positive Early-Stage Lung Cancer

Roche Holding AG Announces Data from the Phase III OCARINA II Study (S31.006) of OCREVUS®? (ocrelizumab)

We Think Roche Holding (VTX:ROG) Can Stay On Top Of Its Debt

Roche Receives FDA Breakthrough Device Designation for Blood Test to Support Early Alzheimer's Disease Diagnosis

Roche Receives FDA Approval for the First Molecular Test to Screen for Malaria in Blood Donors

Roche Holding AG, Annual General Meeting, Mar 12, 2024

Upcoming dividend of CHF9.60 per share

Roche Holding's (VTX:ROG) Shareholders Will Receive A Bigger Dividend Than Last Year

Roche and Alnylam Report Positive Topline Results from the Phase II KARDIA-2 Study in People with Hypertension

Roche Announces FDA Approves Xolair as First and Only Medicine for Children and Adults with One or More Food Allergies

Roche Launches Three New Factor Xa Inhibitor Coagulation Tests to Meet Growing Patient Need

Roche Holding's (VTX:ROG) Shareholders Will Receive A Bigger Dividend Than Last Year

Roche Holding's (VTX:ROG) Soft Earnings Are Actually Better Than They Appear

Full year 2023 earnings: EPS and revenues miss analyst expectations

Dividend increased to CHF9.60

Roche Announces New 72-Week Data from Two Global Phase III Studies, BALATON and COMINO, Evaluating Vabysmo® (Faricimab) in Macular Edema Due to Branch and Central Retinal Vein Occlusion (BRVO and CRVO)

Roche Holding AG Proposes Dividend

Roche Holding AG (SWX:ROG) completed the acquisition of Carmot Therapeutics Inc. from a group of shareholders.

Roche Holding AG (SWX:ROG) completed the acquisition of Carmot Therapeutics Inc. from a group of shareholders.

European Commission Approves Roche's Tecentriq SC, the EU's First PD-(L)1 Cancer Immunotherapy Subcutaneous Injection for Multiple Cancer Types

Market Cool On Roche Holding AG's (VTX:ROG) Earnings

Roche Holding AG to Report Fiscal Year 2023 Results on Feb 01, 2024

Roche Announces New Data from Its CD20xCD3 T-Cell Engaging Bispecific Antibody Programme Were Presented At the 65Th American Society of Hematology Annual Meeting & Exposition

Roche Announces New Data Reinforce the Benefit of Early Preventative Treatment with Hemlibra for Babies with Severe Haemophilia A

Roche Presents Positive Results from the Phase III INAVO120 Study Evaluating Inavolisib in Combination with Palbociclib and Fulvestrant as a First-Line Treatment for People with PIK3CA-Mutation

We Think Roche Holding (VTX:ROG) Can Stay On Top Of Its Debt

Roche Holding AG (SWX:ROG) entered into a definitive merger agreement to acquire Carmot Therapeutics Inc. from a group of shareholders for approximately $2.7 billion.

Roche Expands Hepatitis Diagnostics Portfolio to Help Clinicians Diagnose and Monitor Patients with Acute or Chronic Hepatitis B Infection

Roche Expands Hepatitis Diagnostics Portfolio to Help Clinicians Diagnose and Monitor Patients with Acute or Chronic Hepatitis B Infection

Roche Launches Automated Serology Hepatitis E Virus Tests, Including A Test to Detect Acute Hev Infections, Recommended in the New Who 2023 Essential Diagnostics List

Roche's Subcutaneous Injection of Tecentriq Recommends by the EU's CHMP for Multiple Cancer Types

Roche Announces its Elecsys NfL Test Receives FDA Breakthrough Device Designation from the U.S. Food and Drug Administration

Roche Announces EMBARK Trial in Duchenne Muscular Dystrophy

United States Food and Drug Administration Approves Roche's Vabysmo for the Treatment of Retinal Veinocclusion (RVO)

Roche Holding AG Confirms Outlook for 2023

Roche Announces Roche IL-6 Is the First Immunoassay Approved to Aid Sepsis Diagnosis in Newborns

Roche Announces New Clinical and Real-World Data for Orevus (Ocrelizumab)

Roche Holding AG Announces Late-Breaking Data from the Phase III Ocarina III Study as an Investigational Twice-Yearly, 10-Minute Subcutaneous Injection on Pharmacokinetic, Biomarker, and Mri Measures in Patients with Relapsing or Primary Progressive Multiple Sclerosis

Roche Presents Positive Results from the Primary Analysis of the Ongoing Rainbowfish Study Assessing the Efficacy and Safety of Evrysdi

Roche and Alnylam Report Positive Topline Results from Phase 2 Study Kardia-1 of Zilebesiran

Roche’S Alecensa Delivers Unprecedented Phase III Results for People with ALK-positive early-stage lung cancer

Roche Holding AG Tecentriq Becomes the First Subcutaneous Anti-PD-(L)1 Cancer Immunotherapy Available to Patients in Great Britain, Reducing Treatment Time to Just Minutes

Is Roche Holding (VTX:ROG) A Risky Investment?

Roche Provides Update on Phase III Skyscraper-01 Study in PD-L1-High Metastatic Non-Small Cell Lung Cancer

New minor risk - Earnings quality

Roche Holding AG Confirms Earnings Guidance for the Year 2023

Roche Announces New Clinical and Real-World Data for Vabysmo at ASRS Reveal Improved Outcomes for People with Two Leading Causes of Vision Loss